Unfortunately, clinical trials for combination treatments with Her2 and mTOR pathways in advanced Her2+ breast cancers, despite evidence for prolonged progression-free survival [38, 39], have not yielded changes to the standard treatment due to significant toxicity associated with the combination [5], underscoring the need for alternative targeting strategies. This evidence concerns the gene ERBB2 and breast cancer.